FDA recall D-0308-2025

Breckenridge Pharmaceutical, Inc. · Class II · drug

Product

Duloxetine Delayed-Release Capsules, USP, 30 mg, Rx Only, 1,000 Capsules per bottle, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain, Distributed by: Breckenridge Pharmaceutical, Inc., Berkley Heights, NJ 07922, NDC 51991-747-10.

Reason for recall

CGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.

Distribution

Nationwide in the US

Key facts

Status
Ongoing
Initiation date
2025-03-26
Report date
2025-04-09
Voluntary/Mandated
Voluntary: Firm initiated
Location
Berkeley Heights, NJ, United States

Primary source

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0308-2025